Aspire Biopharma Holdings, Inc.
Aspire Biopharma Holdings, Inc.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Common Class A | - | - | - | - | - | - | - | - | - | - | - | 7 | |||||
Assets | |||||||||||||||||
Cash | 6 | 1 | 2 | 0 | 1 | 0 | - | - | 0 | - | 0 | 0 | |||||
Cash And Cash Equivalents At Carrying Value | 6 | - | - | - | - | - | - | - | - | - | - | - | |||||
Assets Current | |||||||||||||||||
Assets Current | 7 | 1 | 2 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |||||
Prepaid Expense And Other Assets Current | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Inventory Net | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | |||||
Other Receivables | - | - | - | - | - | 0 | 0 | 0 | - | - | - | - | |||||
Assets | 7 | 1 | 2 | 1 | 2 | 0 | 7 | 7 | 20 | 20 | 20 | 21 | |||||
Liabilities And Stockhold… | |||||||||||||||||
Other Liabilities Current | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Accounts Payable And Accrued Liabilities Current | - | - | - | - | - | 1 | 1 | 1 | 0 | 0 | 0 | 0 | |||||
Notes And Loans Payable Current | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - | - | |||||
Accounts Payable Current | 1 | 1 | 1 | 1 | 1 | 0 | - | - | - | - | - | - | |||||
Liabilities Current | |||||||||||||||||
Assets Held In Trust Noncurrent | - | - | - | - | - | 7 | 7 | 7 | 20 | 20 | 20 | 20 | |||||
Liabilities Current | 3 | 8 | 14 | 11 | 10 | 2 | 7 | 6 | 3 | 0 | 0 | 0 | |||||
Accrued Liabilities Current | 0 | 1 | 0 | 0 | 0 | - | - | - | - | - | - | - | |||||
Notes Payable Current | - | - | - | 1 | 1 | - | - | - | - | - | - | - | |||||
Loans Payable Current | - | - | - | 0 | 0 | - | - | - | - | - | - | - | |||||
Derivative Liabilities Current | - | 0 | 4 | - | - | - | - | - | - | - | - | - | |||||
Convertible Debt Current | - | 1 | 5 | 4 | 3 | - | - | - | - | - | - | - | |||||
Liabilities | 3 | 8 | 14 | 11 | 10 | 2 | 7 | 6 | 3 | 0 | 0 | 0 | |||||
Temporary Equity Carrying Amount Attributable To P… | - | - | - | - | - | 7 | 7 | 7 | 20 | 20 | 20 | 20 | |||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | |||||
Stockholders Equity | |||||||||||||||||
Additional Paid In Capital | 34 | 21 | 11 | 11 | 11 | 1 | 9 | 9 | 11 | 11 | 11 | 11 | |||||
Stockholders Equity | 4 | -6 | -11 | -10 | -8 | -2 | -1 | -1 | -0 | -0 | -0 | 0 | |||||
Retained Earnings Accumulated Deficit | -30 | -27 | -23 | -21 | -19 | -3 | -15 | -15 | -14 | -11 | -11 | -11 | |||||
Liabilities And Stockholders Equity | 7 | 1 | 2 | 1 | 2 | 0 | 7 | 7 | 20 | 20 | 20 | 21 | |||||
Common Classa Subject To Redemption | - | - | - | - | - | - | - | - | - | - | - | 2 | |||||
Common Classa Not Subject To Redemption | - | - | - | - | - | - | - | - | - | - | - | 7 | |||||
Common Class B | - | - | - | - | - | - | - | - | - | - | - | -7 | |||||
Common Class A Subject To Redemption | - | - | - | - | - | - | 0 | 0 | - | - | - | - | |||||
Preferred Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | |||||
Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | - | - | |||||
Common Stock Shares Authorized | 490 | 490 | 490 | 490 | 490 | 490 | - | - | - | - | - | - | |||||
Common Stock Shares Issued | 0 | 0 | 5 | 5 | 5 | 0 | - | - | - | - | - | - | |||||
Shares Outstanding | 0 | 0 | 5 | 5 | 5 | 0 | - | - | - | - | - | - | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.81% | 10.70% | - | - | - | - | - | - | - | - | - | - |
| 2025 | 60.08% | 22.69% | 51.26% | 28.32% | -3.76% | -4.01% | -13.21% | 29.25% | -49.76% | -78.42% | 469.47% | 592.63% |
| 2024 | -0.88% | -1.06% | -1.23% | 0.00% | 10.51% | 1.60% | -1.41% | -1.58% | 11.62% | -15.21% | 7.23% | -28.93% |
| 2023 | - | - | - | 3.79% | 2.65% | 2.89% | -0.46% | -0.18% | 0.37% | 0.18% | 1.20% | 1.81% |
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 50+ calculated metrics
Subscribe to unlock 17+ years of data and 50+ calculated metrics
Performance and Valuation Metrics
Metrics | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liquidity Ratios | |||||||||||||||||
| Current Ratio | 2.26 | 0.17 | 0.17 | 0.09 | 0.20 | 0.09 | 0.01 | 0.05 | 0.02 | 0.20 | 0.80 | 1.92 | |||||
| Quick Ratio | 1.86 | 0.13 | 0.14 | 0.02 | 0.14 | 0.00 | 0.00 | 0.05 | 0.00 | 0.00 | 0.00 | 0.44 | |||||
| Working Capital | 3.96M | -6.28M | -11.46M | -9.57M | -7.90M | -1.54M | -6.51M | -5.90M | -2.57M | -322.11K | -62.95K | 261.79K | |||||
Leverage & Debt | |||||||||||||||||
| Debt to Equity | 0.84 | -1.21 | -1.21 | -1.10 | -1.25 | -1.10 | -8.49 | -11.18 | -5.38 | -1.25 | -5.02 | 1.09 | |||||
| Interest Coverage TTM | -0.70 | -2.44 | -8.33 | -22.28 | -58.17 | -9.39 | -4.79 | -3.99 | 6.42 | - | - | - | |||||
| Debt Ratio | 0.46 | 5.86 | 5.77 | 10.72 | 5.05 | 11.41 | 0.99 | 0.91 | 0.13 | 0.02 | 0.02 | 0.01 | |||||
Efficiency & Turnover | |||||||||||||||||
| Asset Turnover TTM | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Per Share Metrics | |||||||||||||||||
| Diluted EPS TTM | -75.07 | -163.76 | -4.15 | -3.83 | -5.39 | -18.99 | -10.07 | -7.94 | 19.72 | 54.24 | - | 100.68 | |||||
| Free Cash Flow Per Share TTM | -39.64 | -32.93 | -0.71 | -0.59 | -0.58 | -3.84 | -13.06 | -7.68 | -9.62 | -7.93 | - | -5.73 | |||||
| Dividend Per Share TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | |||||
Margin Metrics | |||||||||||||||||
| Operating Profit Margin TTM | -15,745.85% | -312,016.95% | -911,777.02% | - | - | - | - | - | - | - | - | - | |||||
| Net Profit Margin TTM | -34,039.68% | -394,725.06% | -1,058,156.83% | - | - | - | - | - | - | - | - | - | |||||
Growth Metrics | |||||||||||||||||
| Net Income Growth (1Y) | -30.89% | 1,768.95% | 2,854.91% | 3,349.34% | -1,350.87% | -129.34% | -110.15% | -106.86% | -78.40% | 33.65% | - | - | |||||
| EPS Growth (1Y) | 1,292.67% | 762.51% | -58.83% | -51.75% | -127.33% | -135.01% | - | -107.89% | -77.50% | -0.56% | - | - | |||||
Valuation Metrics | |||||||||||||||||
| P/E TTM | -0.01 | -0.03 | -1.99 | -2.81 | -4.33 | -24.23 | -48.49 | -56.76 | 22.34 | 8.03 | - | 4.14 | |||||
| P/B TTM | 0.04 | -0.12 | -3.56 | -5.52 | -9.26 | -20.61 | -43.52 | -55.74 | -62.07 | -111.31 | - | 126.38 | |||||
| P/S TTM | 4.67 | 127.27 | 21,024.93 | - | - | - | - | - | - | - | - | - | |||||
| Market Cap | 161.39K | 789.34K | 40.81M | 53.08M | 73.63M | 31.74M | 33.70M | 31.11M | 30.40M | 35.85M | - | 33.08M | |||||
| Enterprise Value | -5.70M | 1.08M | 43.60M | 58.32M | 77.17M | 31.73M | 33.69M | 31.09M | 30.35M | 35.85M | - | 32.96M | |||||
Calculated Values | |||||||||||||||||
| Free Cash Flow TTM | -6.21M | -4.92M | -3.52M | -2.91M | -1.82M | -265.19K | -900.88K | -530.26K | -663.97K | -653.11K | -532.85K | -454.55K | |||||
| Net Debt | -5.86M | 286.57K | 2.79M | 5.24M | 3.54M | -3.63K | -16.54K | -19.60K | -47.29K | 0.00 | -280.00 | -125.20K | |||||
Per-Share and Margin | |||||||||||||||||
| EPS TTM | |||||||||||||||||
| Adjusted EPS TTM | |||||||||||||||||
| Cash Flow Per Share TTM | |||||||||||||||||
| Pretax Margin TTM | |||||||||||||||||
| Stock Comp to Revenue TTM | |||||||||||||||||
Turnover Ratios and Averages | |||||||||||||||||
| Average Assets | |||||||||||||||||
| Average Equity | |||||||||||||||||
| Average Inventory | |||||||||||||||||
| Average Receivables | |||||||||||||||||
| Average Accounts Payables | |||||||||||||||||
| Inventory Turnover TTM | |||||||||||||||||
| Payables Turnover TTM | |||||||||||||||||
| Days Inventory Outstanding TTM | |||||||||||||||||
| Days Payables Outstanding TTM | |||||||||||||||||
| Cash Conversion Cycle TTM | |||||||||||||||||
| Working Capital to Revenue | |||||||||||||||||
| Deferred Revenue to Revenue | |||||||||||||||||
Growth Rates | |||||||||||||||||
| Total Assets Growth (1Y) | |||||||||||||||||
| Total Assets Growth (3Y) | |||||||||||||||||
| Total Assets Growth (5Y) | |||||||||||||||||
| Dividends Paid Growth (1Y) | |||||||||||||||||
| Dividends Paid Growth (3Y) | |||||||||||||||||
| Dividends Paid Growth (5Y) | |||||||||||||||||
| EPS Growth (3Y) | |||||||||||||||||
| EPS Growth (5Y) | |||||||||||||||||
| Net Income Growth (3Y) | |||||||||||||||||
| Net Income Growth (5Y) | |||||||||||||||||
| Net Profit Margin Growth (1Y) | |||||||||||||||||
| Net Profit Margin Growth (3Y) | |||||||||||||||||
| Net Profit Margin Growth (5Y) | |||||||||||||||||
| Net Revenue Growth (3Y) | |||||||||||||||||
| Net Revenue Growth (5Y) | |||||||||||||||||
| Deferred Revenue Growth (1Y) | |||||||||||||||||
| Retained Earnings Growth (1Y) | |||||||||||||||||
Credit, Liquidity, Returns, Payout | |||||||||||||||||
| Cash Ratio | |||||||||||||||||
| Net Working Capital | |||||||||||||||||
| Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to Equity | |||||||||||||||||
| Altman A | |||||||||||||||||
| Altman B | |||||||||||||||||
| Altman C | |||||||||||||||||
| Altman D | |||||||||||||||||
| Altman E | |||||||||||||||||
| Altman Z-Score | |||||||||||||||||
| ROA TTM | |||||||||||||||||
| ROE TTM | |||||||||||||||||
| NOPAT TTM | |||||||||||||||||
| ROIC TTM | |||||||||||||||||
| Effective Tax Rate TTM | |||||||||||||||||
| Payout Ratio TTM | |||||||||||||||||
| Dilution Ratio | |||||||||||||||||
| Retained Earnings to Equity | |||||||||||||||||
| Treasury Stock to Equity | |||||||||||||||||
| Treasury Stock Change (1Y) | |||||||||||||||||
| Accrued to Current Liabilities | |||||||||||||||||
Valuation Ratios | |||||||||||||||||
| P/CF TTM | |||||||||||||||||
| Dividend Yield TTM | |||||||||||||||||
| Free Cash Flow Yield TTM | |||||||||||||||||
| EV EBITDA TTM | |||||||||||||||||
| EV EBIT TTM | |||||||||||||||||
| Stock Compensation TTM | |||||||||||||||||
| Adjusted Net Income TTM | |||||||||||||||||
| Billings TTM | |||||||||||||||||
| Total Debt | |||||||||||||||||
| Invested Capital | |||||||||||||||||
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Aspire Biopharma Holdings, Inc. (ASBP) — SEC Financial Statements & Analysis
Aspire Biopharma Holdings, Inc. (ASBP) is a pharmaceutical preparations company, incorporated in E9. Aspire Biopharma Holdings, Inc. trades on ASBPW: Nasdaq as: ASBP: Nasdaq. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Aspire Biopharma Holdings, Inc. reported a Debt-to-Equity ratio of 0.84x, a Price-to-Sales (P/S) ratio of 4.67x (TTM), a Price-to-Book (P/B) ratio of 0.04 (TTM), at a market cap of $161.39K. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- 0.84x
- P/S TTM
- 4.67x
- P/B TTM
- 0.04
- Market Cap
- $161.39K
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Aspire Biopharma Holdings, Inc. in?
Aspire Biopharma Holdings, Inc. (ASBP) operates in the Pharmaceutical Preparations industry.
What is ASBP's market cap?
Aspire Biopharma Holdings, Inc. (ASBP) has a market capitalization of $161.39K as of 2026-03-31.
What exchange does ASBP trade on?
Aspire Biopharma Holdings, Inc. (ASBP) trades on the ASBPW: Nasdaq.
Where is Aspire Biopharma Holdings, Inc. incorporated?
Aspire Biopharma Holdings, Inc. is incorporated in Cayman Islands.